New Jersey District Court Rules For Ranbaxy In Glaxo Patent Suit
The U.S. District Court for the District of New Jersey has ruled that Ranbaxy Laboratories' generic version of GlaxoSmithKline's antibiotic Ceftin does not infringe patents held by Glaxo....To view the full article, register now.
Already a subscriber? Click here to view full article